Skip to main content
. 2017 Mar 31;31(6):1004–1013. doi: 10.1111/jdv.14163

Figure 2.

Figure 2

Response at Week 60 in Patients Continuously Treated and Withdrawn from Ixekizumab. Per cent responders using non‐responder imputation is shown. (a) IXEQ2W; (b) IXEQ4W. The numbers above the bars are the per cent responders. IXE, ixekizumab; PASI 75, 75% reduction in the Psoriasis Area and Severity Index; PASI 90, 90% reduction in the Psoriasis Area and Severity Index; PASI 100, 100% reduction in the Psoriasis Area and Severity Index; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; sPGA, static Physician's Global Assessment.